Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
A user shared their positive experience with a hair transplant of 2450 grafts, noting improved hairline and density while continuing minoxidil and finasteride. The procedure cost Rs 90000, and others complimented the results.
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
The individual had a hair transplant in Turkey with 4052 grafts, resulting in significant hair growth and increased confidence. They use finasteride, rosemary oil, and vitamins, and are pleased with the natural-looking results, encouraging others to consider similar treatments.
A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.
Microneedling with a dermapen using .3mm needles daily is discussed to enhance minoxidil absorption. Some users reuse cartridges for multiple applications, ensuring cleanliness with alcohol.
The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.
The user experienced significant hair thickening after 9 months using 2.5mg oral minoxidil and 1mg finasteride daily, with minor side effects like increased body hair. They advise patience with finasteride, noting it can take up to a year to see results.
The conversation is about a hair regrowth regimen that includes using minoxidil, peppermint oil, a red light hat, and microneedling. The user is seeking advice on the effectiveness and frequency of these treatments.
PP405 is being discussed as a promising hair loss treatment, potentially effective when combined with minoxidil and pyrilutamide. Some users are skeptical about rapid hair regrowth claims, while others are considering alternatives like GT20029 and pyrilutamide instead of finasteride.
The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.
The user reports significant hair regrowth after 10 months using 1 mg oral finasteride daily and a 1.25 mm derma stamp bi-weekly with rosemary and jojoba oil. Other users commend the progress and inquire about the routine and side effects.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
A 35-year-old male reported positive hair regrowth after 9 months using oral dutasteride 0.5mg and oral minoxidil 5mg daily. A reply emphasized the importance of commitment and consistency for hair regrowth.
The conversation discusses a user's 9-month progress using topical finasteride (0.05%) and minoxidil (5%) with microneedling for hair loss, noting some improvement without side effects. Suggestions include trying oral treatments or switching to topical dutasteride for potentially better results.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.
A user experienced significant hair regrowth after 9 months using 1mg finasteride and daily topical minoxidil, with dandruff as the only side effect. They stressed consulting a healthcare professional before starting treatment.
Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
A 24-year-old has been using finasteride, minoxidil, and ketoconazole shampoo for 9 months to address hair loss, reporting slow but noticeable progress with some regrowth. They also occasionally used a dermastamp and shared photos to show their progress.
The user has been using finasteride and minoxidil for 9 months with minimal regrowth and plans to switch to dutasteride with a higher dose of minoxidil. They are considering a hair transplant to fill in the temples but have received mixed opinions on whether it's necessary.